Luminex (NASDAQ:LMNX) receives ~$5.4M award from the Biomedical Advanced Research and Development Authority or BARDA to conduct product development work and complete filing for Luminex's expanded NxTAG Respiratory Pathogen Panel.
This includes the SARS-CoV-2 virus for high-throughput COVID-19 testing.
Since the COVID-19 pandemic began, Luminex has been committed to expanding capacity for SARS-CoV-2 testing across all of its molecular platforms.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.